BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12801613)

  • 1. Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene.
    Panahloo A; Mohamed-Ali V; Gray RP; Humphries SE; Yudkin JS
    Atherosclerosis; 2003 Jun; 168(2):297-304. PubMed ID: 12801613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study.
    Juhan-Vague I; Morange PE; Frere C; Aillaud MF; Alessi MC; Hawe E; Boquist S; Tornvall P; Yudkin JS; Tremoli E; Margaglione M; Di Minno G; Hamsten A; Humphries SE;
    J Thromb Haemost; 2003 Nov; 1(11):2322-9. PubMed ID: 14629464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction.
    Fu L; Jin H; Song K; Zhang C; Shen J; Huang Y
    Chin Med J (Engl); 2001 Mar; 114(3):266-9. PubMed ID: 11780311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography.
    Ossei-Gerning N; Mansfield MW; Stickland MH; Wilson IJ; Grant PJ
    Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):33-7. PubMed ID: 9012634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes.
    Iwai N; Shimoike H; Nakamura Y; Tamaki S; Kinoshita M
    Atherosclerosis; 1998 Jan; 136(1):109-14. PubMed ID: 9544737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease.
    Catto AJ; Carter AM; Stickland M; Bamford JM; Davies JA; Grant PJ
    Thromb Haemost; 1997 Apr; 77(4):730-4. PubMed ID: 9134651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
    Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
    Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study.
    Burzotta F; Iacoviello L; Di Castelnuovo A; Zamparelli R; D'Orazio A; Amore C; Schiavello R; Donati MB; Maseri A; Possati G; Andreotti F
    J Thromb Thrombolysis; 2003 Dec; 16(3):149-54. PubMed ID: 15087600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde.
    Ye S; Green FR; Scarabin PY; Nicaud V; Bara L; Dawson SJ; Humphries SE; Evans A; Luc G; Cambou JP
    Thromb Haemost; 1995 Sep; 74(3):837-41. PubMed ID: 8571307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene.
    Panahloo A; Mohamed-Ali V; Lane A; Green F; Humphries SE; Yudkin JS
    Diabetes; 1995 Jan; 44(1):37-42. PubMed ID: 7813812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group.
    Hermans PW; Hibberd ML; Booy R; Daramola O; Hazelzet JA; de Groot R; Levin M
    Lancet; 1999 Aug; 354(9178):556-60. PubMed ID: 10470700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
    Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
    Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI-1 gene.
    Mlynarska A; Waszyrowski T; Kasprzak JD
    J Thromb Haemost; 2006 Jun; 4(6):1361-6. PubMed ID: 16706983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
    Grancha S; Estellés A; Tormo G; Falco C; Gilabert J; España F; Cano A; Segui R; Aznar J
    Thromb Haemost; 1999 Apr; 81(4):516-21. PubMed ID: 10235431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of PAI-1 gene promoter-675 (4G/5G) polymorphism on fibrinolytic activity after cardiac surgery employing cardiopulmonary bypass.
    Ozolina A; Strike E; Jaunalksne I; Serova J; Romanova T; Zake LN; Sabelnikovs O; Vanags I
    Medicina (Kaunas); 2012; 48(10):515-20. PubMed ID: 23324247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke.
    Ding J; Nicklas BJ; Fallin MD; de Rekeneire N; Kritchevsky SB; Pahor M; Rodondi N; Li R; Zmuda JM; Harris TB
    Am Heart J; 2006 Dec; 152(6):1109-15. PubMed ID: 17161063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator inhibitor-1 promoter 4G/5G genotype is not a risk factor for myocardial infarction in a Japanese population.
    Sugano T; Tsuji H; Masuda H; Nakagawa K; Nishimura H; Kasahara T; Yoshizumi M; Nakahara Y; Kitamura H; Yamada K; Yoneda M; Maki K; Tatsumi T; Azuma A; Nakagawa M
    Blood Coagul Fibrinolysis; 1998 Mar; 9(2):201-4. PubMed ID: 9622220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: a case-control study.
    Abboud N; Ghazouani L; Saidi S; Ben-Hadj-Khalifa S; Addad F; Almawi WY; Mahjoub T
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):23-7. PubMed ID: 19929406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients.
    Menges T; Hermans PW; Little SG; Langefeld T; Böning O; Engel J; Sluijter M; de Groot R; Hempelmann G
    Lancet; 2001 Apr; 357(9262):1096-7. PubMed ID: 11297964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study.
    van Goor ML; Gómez García E; Leebeek F; Brouwers GJ; Koudstaal P; Dippel D
    Thromb Haemost; 2005 Jan; 93(1):92-6. PubMed ID: 15630497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.